Fondaparinux: A cornerstone drug in acute coronary syndromes

doi:10.4330/wjc.v14.i1.40

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7055)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-10) series.

Item

Count

PDF

598

WORD

100

HTML

4419

Figures (1-6)

216

Tables (1-10)

185

Sum=5518

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

293

Download

510

Sum=803

Publishing Process of This Article

Item

Count

Browse

313

Download

421

Sum=734

Jan 26, 2022 (publication date) through Apr 29, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. Jan 26, 2022; 14(1): 40-53
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40

Full Size Figure Download Figure

Figure 4 Primary composite outcome. Death or reinfarction was significantly lower in the Fondaparinux group compared with the control group at 30 d and at 3 or 6 mo.

Citation: Khan MY, Ponde CK, Kumar V, Gaurav K. Fondaparinux: A cornerstone drug in acute coronary syndromes. World J Cardiol 2022; 14(1): 40-53
URL: https://www.wjgnet.com/1949-8462/full/v14/i1/40.htm
DOI: https://dx.doi.org/10.4330/wjc.v14.i1.40